Address
33-17, Q Sentral.
2A, Jalan Stesen Sentral 2, Kuala Lumpur Sentral,
50470 Federal Territory of Kuala Lumpur
Contact
+603-2701-3606
info@linkdood.com
Google’s battle with U.S. regulators is heating up. In August 2024, a federal judge ruled that Google illegally monopolizes online search. Now, a remedies trial in Washington, D.C., wrapped up in late May 2025. The big question: How do we…
As generative-AI models proliferate and competition intensifies, veteran tech investor Mary Meeker has sounded the alarm: even industry giants like OpenAI could be undercut by more cost-effective challengers. In her latest analysis, Meeker cautions that the current market dynamics—soaring training…
The White House’s new MAHA Report—led by Health Secretary Robert F. Kennedy Jr.—was meant to diagnose America’s declining life expectancy. Instead, it exposed a glaring risk: AI-generated citations that turned solid science into junk. With dozens of fake, duplicated, or…
Saudi Arabia is flexing its financial muscle to become a top-tier player in artificial intelligence. Backed by the $940 billion Public Investment Fund (PIF) and spearheaded by a newly formed state AI company called Humain, the kingdom plans an unprecedented…
Microsoft’s Build conference this year wasn’t just another developer showcase—it was a clear declaration that the software giant now leads the AI revolution. With an all-star lineup of partners and rivals on its stage, Microsoft demonstrated why it’s the go-to…
Sir Jony Ive, the visionary designer behind the iPhone, iPod and Apple Watch, has joined forces with OpenAI’s Sam Altman in a landmark $6.4 billion deal. Ive sold his hardware startup io to OpenAI and will steer design across both…
OpenAI has agreed to acquire io, the AI-focused hardware startup co-founded by legendary Apple designer Jony Ive, in an all-equity transaction valued at $6.5 billion. It’s OpenAI’s largest acquisition to date and marks a bold push into creating purpose-built AI…
OpenAI and the U.S. Food and Drug Administration (FDA) have reportedly engaged in discussions to explore the integration of artificial intelligence (AI) into the FDA’s drug evaluation processes. These talks are part of a broader initiative to modernize and expedite…
The New Problem No One Saw Coming: AI Hallucinations As AI tools like OpenAI’s ChatGPT and Google’s Gemini grow more powerful, they’re not just dazzling us with complex answers—they’re also spinning yarns. These fabrications, known as AI hallucinations, are when…
Artificial intelligence is getting smarter, but it’s also getting hungrier. A new report from MIT Technology Review, illustrated with four key charts, reveals just how fast AI’s energy consumption is climbing—and the surprising sectors feeling the impact. 1. AI’s Energy…